SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell ther...
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.
Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investment prospects.
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of induce...
Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money.
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.